Aliskiren, the future of renin-angiotensin system blockade?

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hypertension Research

Background:

• Renin-angiotensin system (RAS) inhibitors like ACE inhibitors and ARBs are standard hypertension treatments.
• Blocking the angiotensin I receptor can lead to increased plasma renin activity due to loss of negative feedback.
• Previous direct renin inhibitors faced challenges with potency, bioavailability, and half-life.

Purpose of the Study:

• To evaluate the efficacy and pharmacokinetic profile of Aliskiren, a novel direct renin inhibitor.
• To assess Aliskiren's potential for end-organ protection in hypertensive patients.

Main Methods:

• Administration of Aliskiren, a novel direct renin inhibitor, in a once-daily oral dosage.
• Measurement of plasma renin activity to assess renin inhibition.
• Evaluation of pharmacokinetic properties and end-organ protection markers.

Main Results:

• Aliskiren demonstrated efficacy in hypertensive patients with once-daily oral dosing.
• The drug exhibited favorable pharmacokinetic properties.
• Aliskiren showed potential for improving end-organ protection.

Conclusions:

• Aliskiren represents a promising new therapeutic option for hypertension management.
• Its direct inhibition of renin offers a distinct mechanism compared to existing RAS blockers.
• Favorable pharmacokinetics and potential end-organ benefits warrant further investigation.